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Abstract
The levels and activity of c-Src in colorectal cancer cells
increasesteadilyduring thecourseof colorectal carcino-
genesis and are most highly elevated in advanced
metastatic disease. However, the effects of increases
in c-Src activity on the proliferation of colorectal cancer
cells during early and late stages of tumorigenesis re-
main elusive. To study the consequences of increases
in c-Src levels and activity on the growth of colorectal
cancer cells in later stages of colorectal carcinogenesis,
we developed human colorectal cancer cell lines in
which c-Src levels and activity could be inducibly in-
creased by a tightly controlled expression of wild-type
c-Src or of the constitutively active mutant of c-Src,
c-SrcY527F. Src induction activated multiple signaling
pathways (often associated with a proliferative re-
sponse) but promoted neither cell proliferation in vitro
nor tumor growth in a xenograft model in vivo. These
results indicate that, in more advanced stages of colo-
rectal carcinogenesis, increases in c-Src levels and ac-
tivity are likely to have functions other than the direct
promotion of tumor growth.
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Introduction
The nonreceptor tyrosine kinase c-Src is a ubiquitously
expressed 60-kDa protein that can regulate many signaling
pathways involved in the control of cell proliferation, sur-
vival, differentiation, adhesion, and motility [1,2]. c-Src–
mediated cell signaling is not restricted to its ability to act
as a kinase but also involves its function as a scaffold for
protein–protein interactions. Both kinase-dependent and
kinase-independent functions of c-Src are regulated by
multiple mechanisms and contribute to a plethora of cel-
lular processes in a variety of cell types (reviewed in Thomas
and Brugge [3] and Erpel and Courtneidge [4]). Abnormal
c-Src protein levels and/or catalytic activities have been
found in a number of human tumors, including breast, lung,
skin, pancreas, and colon tumors [5–7].
In more than 70% of colorectal cancers, the levels and
activity of c-Src are upregulated 5 to 40 times compared to
neighboring normal mucosa and increase steadily in the course
of tumor development, reaching the highest level in metastatic
malignancies [2,8–11]. A high activity of c-Src has been corre-
lated with poor clinical prognosis [12].
The functions of c-Src that are important in the early stages
of colorectal carcinogenesis remain largely unexplored, not the
least because model systems with which to investigate these
are rare and technically challenging. Increases in c-Src activity
in more advanced tumors seem to play a role in the modulation
of cell –cell and cell–extracellular matrix interactions, and
mounting evidence points to important function(s) of c-Src in
invasion and metastasis [13–17].
Although themitogenic response to v-Src signaling has been
established in fibroblasts [1,2,18–20], uncertainty remains with
regard to the impact of increased c-Src activity on colorectal
cancer cell growth. The few studies that used colon cancer cell
lines stably transfected with constitutively expressed mutants
of c-Src did not provide conclusive answers to growth-related
questions due to adaptation issues during the selection of
stable clones and difficulties regarding matched control clones
[15,21]. Using an inducible gene expression approach, we have
been able to assess more directly the effects of increases in
c-Src levels and activity on the growth of two human colorectal
cancer cell lines that display significantly different morphologic
and molecular characteristics (HCT116 and SW480) [22]. Our
data support the hypothesis that, in more advanced stages of
colorectal carcinogenesis, increases in c-Src levels and activity
do not directly promote tumor cell growth. This finding has
important clinical implications in view of considerable activity
in the development and clinical testing of c-Src inhibitors as
anticancer drugs.
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Materials and Methods
Plasmid Vectors
The construction and properties of pN1pb-actin-rtTA2S-
M2-IRES-EGFP, pBILuc, and pBILuc-Src527F plasmids
have been described previously [23]; the pBILuc-wtSrc
plasmid is identical to pBILuc-Src527F but contains wild-type
(wt) c-Src instead of mutant c-SrcY527F. The super module
vectors pSMVLuc-Src527F, pSMVLuc-wtSrc, and pSMVLuc-
only were generated by AseI-based fusion of the pN1pb-
actin-rtTA2S-M2-IRES-EGFP plasmid with Dox-inducible
modules derived from pBILuc-Src527F, pBILuc-wtSrc, and
pBILuc, respectively (Figure 1A).
Cell Culture and Transfection
HCT116 and SW480 cells were grown in McCoy’s 5A and
DMEM media (Gibco/Invitrogen, Paisley, UK), respectively.
The media were supplemented with 10% fetal calf serum,
100 U/ml penicillin, and 100 mg/ml streptomycin.
Transfections were performed by mixing 20 mg of plasmid
DNA with f2  107 cells suspended in 400 ml of Optimem
with Glutamax (cat. no. 51985-026; Gibco/Invitrogen) in a
4-mm electroporation cuvette (cat. no. ECU104; Equibio,
Ashford, UK) and by electroporation (simple pulse, 260 V,
1050 mF) using an EasyjecT Plus electroporator (Equibio).
Selection of Stable Cell Lines, Luciferase Assay,
and Microscopy
Stable cell populations were generated by the selection of
cells transfected with indicated pSMV plasmids in media con-
taining 800 mg/ml G418 (cat. no. 11811-031; Gibco/Invitrogen)
for 14 to 16 days, followed by 7 to 10 days of growth in the
absence of G418 and flow cytometric sorting of enhanced
green fluorescent protein (EGFP+) cells. Single-cell clones
were picked using sterile cotton buds after low-density seeding
in Petri dishes and were expanded to establish independent
cell lines suitable for Dox-regulated expression of luciferase
(Luc-only clones) or luciferase in combination with wt c-Src
(Luc-wtSrc clones) or c-SrcY527F mutant (Luc-Src527F
clones). Established single-cell clones were screened for
functionality by luciferase assay and Western blot analysis
using anti-Src antibody.
Luciferase assays were performed using the Luciferase
Assay System (cat. no. E1500; Promega, Madison, WI) fol-
lowing the manufacturer’s instruction.
Light and fluorescent microscopy studies were carried out
as described previously [24].
Electron microscopy was performed as described pre-
viously, with minor modifications [25]. (See supplementary
information for a more detailed description.)
Doxycycline (Dox) Treatments
Dox (cat. no. 8634-1) was obtained from Clontech (Palo
Alto, CA) and stored at 20jC as a 2-mg/ml stock in H2O.
Cells were plated at 1  106 cells/3 ml of medium per well
in six-well plates (Corning, Corning, NY). After 20 to 24 hours,
the medium was replaced with 3 ml of fresh medium with or
without 2 mg/ml Dox. Detached and adherent cells were
counted with a hemocytometer 24 to 30 hours later. Alter-
natively, the cells were dissolved directly in 2 sodium
dodecyl sulfate (SDS) sample buffer or cell lysis buffer (cat.
no. 9803; Cell Signalling, Danvers, MA), and lysates were
analyzed by SDS polyacrylamide gel electrophoresis (PAGE)
and Western blot analysis.
Four-day ± Dox growth curves were determined after
seeding cells at 4  105/3 ml of medium per well in six-well
plates. After 24 hours (day 1), the medium was replaced with
3ml of freshmediumwith or without 1 mg/ml Dox, and the cells
were counted with a hemocytometer daily for 3 days.
To establish whether HCT116 Luc-Src527F cells were
able to overcome growth delay caused by high levels of
c-SrcY527F mutant, HCT116 Luc-Src527F high clones (with
Luc-only and parental HCT116 cells used as controls) at
f70% confluency in T75 tissue culture flasks were induced
with Dox for 24 hours. Subsequently, the cells were split
1:1.5 to 1:4 every second day into new flasks containing
fresh medium with Dox. Six to 8 days of such treatment
resulted in a cell population that proliferated and displayed
little cell detachment.
Detection of Apoptosis
Quantitation of cells displaying apoptotic nuclear fragmen-
tation was performed by embedding adherent cells (grown on
glass coverslips) and detached cells in Vectashield mounting
medium containing DAPI (Vector Laboratories, Burlingane,
CA) and by subsequently inspecting under a fluorescent
microscope equipped with a DAPI filter.
M30-Apoptosense enzyme-linked immunosorbent assay
(ELISA) assay is an ELISA for the quantitative measurement
of apoptosis in cells of epithelial origin that express cyto-
keratin 18 (CK18; Peviva, Bromma, Sweden). Mouse mono-
clonal M30 antibody recognizes a neoepitope CK18-Asp396,
which is exposed after the cleavage of CK18 by caspases
[26]. The assay was performed as follows: cells were plated
Figure 1. Construction and use of super module vector for the induction of c-SrcY527F in human colon cancer cells. (A) Schematic illustrating the construction and
structural features of the pSMVLuc-Src527F vector. The plasmid map of pSMVLuc-Src527F shows component elements of the vector, including a -actin
promoter-driven EGFP-linked module expressing rtTA2S-M2 transcriptional transactivator, a kanamycin/neomycin resistance cassette, and a bidirectional
promoter –based module expressing luciferase and c-SrcY527F in a Dox-dependent manner. (B) Comparison of endogenous c-Src levels in HT29, WiDr, HCT116,
and SW480 colon cancer cell lines. Int 407 cells represent a nontransformed human intestinal epithelial cell line [37]. (C) c-SrcY527F induction in representative
HCT116 Luc-SrcY527F clones determined after 24 hours in the presence of Dox. (D) Growth characteristics of parental wt HCT116 cells and selected HCT116
Luc-only, Luc-wtSrc, and Luc-SrcY527F clones in the absence of Dox. Growth curves were determined after seeding 1  105 cells/well in six-well plates. Data are
representative of three independent experiments performed in triplicate. Error bars represent standard deviations. For better transparency, the growth curves for
each clone are also presented individually in Figure W4. Figure 1 contains a supplementary panel (Figure W1) illustrating the phosphorylation of diverse
downstream effectors of c-Src in selected HCT116 clones in the presence and in the absence of Dox.
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at 1  106 cells/well in six-well plates. After 24 hours, the
medium was replaced with 2 ml of fresh medium containing
2 mg/ml Dox, and cells were incubated for another 24 hours.
Negative control consisted of cells in a medium without Dox,
and positive control consisted of cells treated with stauro-
sporine (35 nM) in the absence of Dox (this staurosporine
concentration produced 50% apoptosis in HCT116 cells).
Subsequently, 1 ml of medium was removed from each well
and spun down at 1000 rpm for 5 minutes in a standard
bench-top centrifuge, and the resultant supernatant was
stored at 80jC before analysis. Each M30-Apoptosense
assay kit contained a 96-well plate coated with a mouse
monoclonal antibody to CK18, standards, quality controls,
and reagents. Twenty-five microliters of each sample, con-
trol, or standard was pipetted into a well, and 75 ml of
horseradish peroxidase conjugate solution [mouse mono-
clonal M30 antibody in phosphate-buffered saline (PBS) with
protein stabilizers] was added. The plate was then incubated
for 4 hours at room temperature with constant shaking
(600 rpm). Each well was washed five times with 0.1%
PBS-T; 200 ml of 3,3V,5,5V-tetramethyl-benzidine substrate
solution was added; and the plate was incubated in the dark
for 20 minutes. The reaction was stopped by adding 50 ml of
1 M sulfuric acid, and absorbance was measured in a micro-
plate reader at 450 nm. The amount of M30 antigen in each
sample was calculated by interpolation based on a five-point
standard curve of known concentrations of M30 antigen.
Cell Cycle Analysis
Cell cycle analysis has been performed essentially as
described previously, with minor modifications [23]. (See
supplementary information for a more detailed description.)
Antibodies, Gel Electrophoresis, and Western Blot Analysis
SDS-PAGE was performed using 10% or 12.5% polyacryl-
amide gel. Proteins were blotted onto polyvinylidene fluoride
membrane (PVDF) membranes (Perkin-Elmer, Boston, MA)
and incubated with appropriate first antibody and horseradish
peroxidase–coupled anti-mouse or anti-rabbit secondary IgG
(Dako, Glostrop, Denmark). The following primary antibodies
have been used: monoclonal mouse anti–v-Src (cat. no.
OP07; Oncogene Research Products, Nottingham, UK); poly-
clonal rabbit anti–Src [pY418] (cat. no. 44-660; Biosource,
Camarillo, CA); polyclonal rabbit anti-Cdk1 (cat. no. 9112),
polyclonal rabbit anti–P-Cdk1 (Tyr15) (cat. no. 9111), poly-
clonal rabbit anti–Erk1/2 (cat. no. 9102), monoclonal mice
anti–P-Erk1/2 (Thr202/Tyr204) (cat. no. 9106), polyclonal
rabbit anti-PKB (cat. no. 9272), polyclonal rabbit anti–P-PKB
(Ser473) (cat. no. 9271), polyclonal rabbit anti–histone H3
(cat. no. 9715), polyclonal rabbit anti–P-histone H3 (Ser10)
(cat. no. 9701), polyclonal rabbit anti-STAT3 (cat. no. 9132),
and polyclonal rabbit anti–PSTAT3 (Tyr405) (cat. no. 9131; all
from Cell Signalling); mouse monoclonal anti-paxillin (cat.
no. 610051; BD Biosciences Pharmingen, San Diego, CA);
rabbit polyclonal anti-paxillin [pY31] (cat. no. 44-720; Bio-
source); polyclonal rabbit anti-Src (cat. no. 44-6556; Bio-
source); and mouse monoclonal anti-actin (cat. no. A-4700;
Sigma, Poole, UK).
Tumor Xenografts
HCT116 Luc-wtSrc 23 and HCT116 Luc-Src527F HighY50
cells were grown as subcutaneous xenografts in 8-week-
old female Balb/c-NUDE nude mice (Paterson Institute for
Cancer Research, Manchester, UK) following the injection of
5  106 cells in 0.1 ml of Optimem. Mice were housed in an
individually ventilated caging system on a 12-hour light/dark
environment maintained at constant temperature and hu-
midity. The animals were fed a standard diet (controls) or
a Dox-containing diet (625 mg/kg TD 01306; Harlan-Teklad,
Madison, WI), and tumor volume (defined as length width
height) was measured every second day. When tumor volume
exceeded 800 mm3, the mice were sacrificed and samples of
tumors were snap-frozen for subsequent luciferase assay. All
procedures were carried out in accordance with UKCCCR
guidelines 1999 by approved protocol (Home Office Project
license no. 40-2746).
Results
A Rapid, Single-Step, Nonviral System for Inducible
Gene Expression in Cancer Cells
To investigate the consequences of increases in c-Src
levels and activity on the growth of human colorectal cancer
cells, we further enhanced the advantages of our recently
reported two-step modification of the Tet On system [23,27].
By fusing the previously described pN1pb-actin-rtTA2S-M2-
IRES-EGFP and pBILuc-wtSrc or pBILuc-Src527F plasmids,
single super module vectors (pSMVLuc-wtSrc or pSMVLuc-
Src527F, respectively) were obtained. They were designed
for simultaneous Dox-dependent expression of the indicated
c-Src protein (wt or constitutively active mutant) and firefly
luciferase (used as reporter) (Figure 1A). These plasmids
were transfected into HCT116 human colorectal cancer cells.
HCT116 cells (similar to SW480 cells that will be described
later) display relatively low levels of endogenous c-Src com-
pared to some other colorectal cancer cell lines of similar
stage and thus represent an appropriate model for functional
studies on the effects of increases in c-Src levels and activity
(see Figure 1B and the data presented in Dehm et al. [28]).
Following selection in the presence of G418 and EGFP-
based cell sorting (for details, see the Materials and Methods
section), a large number (>100) of stably transfected clones
were established. More than 25% of these clones displayed
good Dox-driven inducibility with respect to wt c-Src or
c-SrcY527F. The basal leakiness of gene expression in the
majority of clones was very low or undetectable (Figure 1C
and data not shown). For practical reasons, further studies
were limited to two clones expressing wt c-Src (Luc-wtSrc
clones wt23 and wt28), two clones expressing low levels
of c-SrcY527F (Luc-Src527F clones LowX43 and LowY12),
four clones expressing high levels of c-SrcY527F (Luc-
Src527F clones HighX45, HighX53, HighY50, and HighY51),
and two control clones established after the transfection of
HCT116 cells with the pSMVLuc-only plasmid that expresses
luciferase only (Luc-only clones LucB20 and LucC6). In the
majority of experiments, we also included parental HCT116
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cells as additional control. To our knowledge, the SMV
system represents the first available single-step nonviral
strategy ensuring a highly successful generation of tightly
controlled Dox-inducible gene expression in a less tractable
andmore unpredictable human cancer cell context. As shown
in Figure 1D, in the absence of induction, all selected cell lines
displayed growth kinetics comparable to parental HCT116
cells, indicating that the geneticmanipulations performed had
not affected their basic growth characteristics.
Src Induction Activates Multiple Signaling Pathways
Src is known to influence multiple signaling pathways. As
expected, inducible expression of wt c-Src and c-SrcY527F in
HCT116 cells resulted in increased phosphorylation of sev-
eral known downstream effectors, including other kinases
(Erk and PKB/Act), the cytoskeletal protein paxillin, and the
transcriptional regulator STAT3 (Figure W1).
Inducible Expression of wt c-Src and Low Levels
of c-SrcY527F Do Not Effect the Proliferation
of HCT116 Cells In Vitro
We examined the consequences of the expression of wt
c-Src on cell growth. As shown in Figure 2, even induction of
high levels of wt c-Src did not effect the proliferation of
HCT116 cells, demonstrating that rises in c-Src levels per
se are unable to confirm any proliferative advantage or
disadvantage to these colorectal cancer cells. Considering
the plentiful published studies performed using mouse or
chicken fibroblasts that strongly indicated a need for sus-
tained high Src activity to trigger reduction in cell doubling
times and increased cell proliferation [1,2,18–20], we sub-
sequently analyzed HCT116 clones expressing a constitu-
tively active mutant of c-Src (c-SrcY527F). Initially, HCT116
Luc-Src527F LowX43 and LowY12 clones that are induced to
express relatively low levels of c-SrcY527F (less than a 3-fold
increase compared to endogenous c-Src for clone LowX43
and less than a 10-fold increase for clone LowY12) were
examined (Figure 2A). Despite clear increases in the amount
of active autophosphorylated c-Src following Dox-mediated
induction, we did not observe any changes in cell proliferation
kinetics or cell cycle profiles (Figure 2; Figure W2).
Inducible Expression of High Levels of c-SrcY527F Delays
the Growth of HCT116 Cells In Vitro
Subsequently and again to reflect previous fibroblast-
based studies with v-Src, we assessed the consequences
of higher-level induction of c-SrcY527F on the growth of
HCT116 cells. For these experiments, clones HCT116 Luc-
Src527FHighX45, HighX53, HighY50, andHighY51, inwhich
Dox-mediated induction of c-SrcY527F resulted in highly in-
creased (>10 times) levels of total and autophosphorylated
active c-Src (Figure 3B), were selected. Highly elevated
levels of constitutively active c-Src resulted in spread of ad-
herent cells, where a proportion of cells possessed large
EGFP-free vesicular structures (Figure 3A). In addition, there
was a clear increase in the number of cells that detached
from monolayer (Figure 3, A and C). Control Luc-only and wt
cells (similar to HCT116 Luc-wtSrc and Luc-Src527F Low
cells described in the Inducible Expression of wt c-Src and
Low Levels of c-SrcY527F Do Not Effect the Proliferation of
HCT116 Cells In Vitro section) did not display any changes in
cell morphology when treated with Dox (Figure 3A), nor did
they display any increased detachment (Figure 3C). When
cells were counted 24 to 72 hours postinduction, the total
number of cells in induced Luc-Src527F High clones was
significantly lower than that in the same untreated cells
(Figure 3, C and D). Over the same period of time, there
were no differences between induced and uninduced sam-
ples within control Luc-only cell lines and parental HCT116
cells (Figure 3, C and D), suggesting that high increases in
levels of constitutively activated c-Src had negative con-
sequences on the growth of HCT116 cells in vitro. A more
detailed analysis demonstrated that this resulted from accu-
mulation in the G2 phase of the cell cycle (confirmed by cell
cycle profile, increased phosphorylation of Cdk1 on Tyr15,
and decreased phosphorylation of histone H3 on Ser10) and
occurrence of a nonapoptotic form of cell death (confirmed by
M30-Apoptosense ELISA assay, DAPI staining, and electron
microscopy) (Figure 4; Figure W3).
The identification of negative effects of high levels of
c-SrcY527F on the in vitro growth of HCT116 cells was
somewhat surprising considering that previous studies with
v-Src in fibroblasts predicted the opposite effect and consid-
ering the fact that stable colorectal cancer cell lines that
highly overexpress this constitutively active mutant of c-Src
have been described in the past [15,29]. The ability of
HCT116 cells to overcome c-SrcY527F–dependent growth
delay when exposed to high levels of this activated c-Src
mutant over prolonged periods of time was explored. The
growth delay phenomenon appeared to last for 6 to 8 days
when Dox-induced Luc-Src527F High clones were seeded at
high density and split every second day. During this time,
many cells died and were discarded. The fraction of cells that
survived (mimicking perhaps the selection of stable clones)
proliferated, and the rate of cell detachment decreased. The
morphology of these cells (continuously induced and thus still
overexpressing constitutively active Src) more closely resem-
bled that of cells before c-SrcY527F induction (Figure 5A).
To determine whether increased levels of constitutively active
c-Src had any effect on the growth of these continuously
induced cells, their growth properties were assessed in the
presence and in the absence of Dox and were compared
to those of control Luc-only cells and parental HCT116 cells
under identical conditions. If at all, c-SrcY527F maintained
reduced growth delay and certainly did not promote cell
proliferation (Figure 5B). Thus, our studies to this point
showed that induced expression of wt c-Src or of low levels
of c-SrcY527F does not promote the proliferation of HCT116
cells and that high-level induction of this active mutant delays
growth and promotes nonapoptotic cell death.
Inducible Expression of Activated Src Does Not Promote
the Growth of SW480 Cells In Vitro
To confirm if lack of the growth-promoting effects of
elevated Src activity observed in HCT116 cells was not a cell
type–specific phenomenon, several Luc-Src527F clones
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were generated in the SW480 human colon cancer cell
background. SW480 cells differ significantly from HCT116
cells with respect to molecular abnormalities associated with
transformed phenotype. We were able to establish SW480
cells inducing low and high levels of activated c-Src. Similar to
the results obtained in HCT116 cells, in SW480 cells, low-
level induction of c-SrcY527F did not have any noticeable
effects on cell proliferation, whereas high-level induction was
growth-inhibitory (Figure 6).
Neither Induction of wt c-Src Nor Induction of c-SrcY527F
Promotes the Growth of HCT116 Tumor Xenografts
The experiments described so far demonstrated that
increases in the levels and activity of c-Src do not promote
the proliferation of HCT116 and SW480 cells in vitro. To
assess the consequences of Src upregulation on cell growth
in a more complex in vivo microenvironment, we grew
HCT116 clones inducing wt c-Src and constitutively active c-
SrcY527Fmutant (HCT116 SMVLuc-wtSrc wt23 and HCT116
Figure 2. Consequences of the overexpression of wt c-Src and the low-level induction of c-SrcY527F in HCT116 colorectal cancer cells. (A) Western blot
analyses illustrating the levels of total and autophosphorylated active Src [Tyr416] in indicated clones 24 hours after induction. (B) Histogram showing no
changes in cell proliferation 24 hours following high-level induction of wt c-Src (clones wt23 and wt28) and low-level induction of c-SrcY527F (clones LowX43 and
LowY12). Data are based on three independent experiments performed in triplicate. No statistically significant differences were found between numbers of cells
in the presence and in the absence of Dox for any of the clones (two-sided t-tests, P > .05). (C) Four-day growth curves of HCT116 Luc-wtSrc (clone wt28) and
HCT116 Luc-Src527F (clone LowX43) cells grown in the absence and in the presence of Dox. The initial seeding density was 4  105 cells/well. Data are
representative of three independent experiments performed in triplicate. The cell cycle profiles of HCT116 Luc-wtSrc cells and HCT Luc-Src527F Low cells are
presented in Figure W2.
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Figure 3. Consequences of the high-level induction of c-SrcY527F in HCT116 colorectal cancer cells. (A) Representative pictures of HCT116 Luc-Src527F High
(clone HighY50) and control HCT116 Luc-only (clone LucC6) cells 24 hours after induction. Fluorescent microscopy insert illustrates lack of EGFP signals in
vesicles formed after a high-level expression of c-SrcY527F. (B) Western blot analyses showing increases in the expression level of total and autophosphorylated
c-Src [Tyr416] 24 hours after induction in HCT116 Luc-Src527F High clones but not in HCT116 Luc-only controls and wt HCT116 cells. (C) Quantification of
adherent and detached cells in indicated Dox-induced and uninduced HCT116 Luc-Src527F High clones, HCT116 Luc-only control cell lines, and parental HCT116
wt cells. Cell counts were performed 24 hours after induction, and data are based on three independent experiments performed in triplicate. All HCT116 Luc-
Src527F High clones displayed significantly decreased total cell numbers and increased numbers of detached cells following induction with Dox (two-sided t-tests,
P < .01). A slight decrease in total cell number following Dox treatment was also observed for clone HCT116 Luc-only C6 (P < .05), but this was caused by a
mechanism different from that observed for HCT116 Luc-Src527F High clones (Figure 4). (D) Four-day growth curves of HCT116 Luc-Src527F HighY50 cells, and
HCT116 Luc-only, and LucB20 controls grown in the absence and in the presence of Dox. The initial seeding density was 4  105 cells/well. Data are
representative of three independent experiments performed in triplicate.
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SMVLuc-Src527F HighY50, respectively) as xenografts in
nude mice. As illustrated in Figure 7, neither induction of wt
c-Src nor induction of c-SrcY527F resulted in any growth-
promoting effects in HCT116 tumor xenografts. If anything,
tumors induced to express c-SrcY527F displayed growth
slower than those of their uninduced counterparts (Fig-
ure 7B). Taken together, these data suggest that increases
in c-Src levels and activity are unlikely to promote the growth
of HCT116 cells in vivo.
Discussion
A large body of evidence links aberrant Src signaling to the
development and progression of a variety of human tumors,
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making c-Src an attractive target for cancer chemotherapy
[2,5–7,30]. Indeed, small molecule inhibitors of c-Src display
anticancer activity in vitro and in xenograft models in several
experimental systems, and candidate drugs are approaching
or have recently entered phase I clinical trials worldwide [31].
The success and efficiency of Src-focused therapeutic strat-
egies rely on a thorough understanding of Src function in
relevant human cancer cell contexts. Until very recently, the
majority of function testing studies of Src were performed in
fibroblasts and/or used the viral homologue v-Src, rather than
the c-Src proto-oncogene [2]. Human cancers are predomi-
nantly of epithelial origin and, in recent years, it has become
evident that epithelial cells differ from fibroblasts in many as-
pects of cellular behavior [32,33]. Thus, there is a pressing
Figure 4. Effects of a high-level induction of c-SrcY527F on cell cycle profile and cell viability in HCT116 colorectal carcinoma cells. (A) Cell cycle profiles of
HCT116 Luc-only cells (clone LucB20) and HCT116 Luc-Src527F cells (clone HighY50) obtained after 24 hours of growth in the presence or in the absence of Dox.
Data are representative of three independent experiments. Results obtained with other Luc-only and Luc-Src527F High clones analyzed were similar to those using
clones LucB20 and Luc-Src527F HighY50, respectively. (B) Histogram illustrating relative increases in the percentage of cells in the G2/M phase of the cell cycle
after 24 hours of growth in the presence of Dox in HCT116 Luc-Src527F High cells but not in control HCT116 Luc-only clones. Data are based on three
independently obtained cell cycle profiles. Western blot analyses show an accompanying decrease in levels of phosphorylated histone H3 [P-Ser10] and an
increase in the phosphorylation of Cdk1 [P-Tyr15], confirming the accumulation of cells in the G2 phase rather than in the M phase of the cell cycle [38]. They are
representative of three repeat experiments. (C) Increases in the percentage of dead cells 24 and 48 hours after induction with Dox in HCT116 Luc-Src527F High
cells but not in control clones. Determined using trypan blue exclusion method. Representative of three independent experiments performed in triplicate. (D)
Histogram illustrating the levels of apoptosis-associated M30 antigen in the conditioned medium of indicated HCT116 Luc-Src527F High clones, control Luc-only
cell lines, and parental wt HCT116 cells grown for 24 hours in the absence or in the presence of Dox. Staurosporine (35 nM)– treated cells represent positive
control for ~50% apoptotic cells. Data are representative of three independent experiments performed in triplicate. Lack of apoptotic phenotype following a high-
level induction of c-SrcY527F was also independently confirmed by DAPI staining (Figure W3). (E) Representative electron microscopy pictures illustrating
ultrastructural changes occurring in HCT116 cells following a high-level induction of c-SrcY527F.
Figure 5. Increased levels and activity of Src do not promote the growth of the fraction of HCT116 Luc-Src527F cells that overcame the growth delay induced by a
high-level expression of c-SrcY527F. (A) Schematic illustrating the generation and morphologic properties of ‘‘post –growth-delay’’ cells. Western blot analyses
show the levels of total and autophosphorylated [Tyr416] Src in ‘‘post –growth-delay’’ cells and matched controls grown for 6 days in the presence or in the absence
of Dox (end point of experiments presented in B). (B) Growth properties of ‘‘post –growth-delay’’ HCT116 Luc-Src527F High cells (clones HighX45 and HighY50)
maintained for 6 days in the presence or in the absence of Dox. Identically treated HCT116 Luc-only cells (clone LucB20) and wt HCT116 cells were used as
controls. The initial seeding density was 1  105 cells/well in a six-well plate, and the medium was replaced by fresh medium on day 3. For each day, data are
presented as the ratio of total cell number in the presence of Dox to the total number of the same cells in the absence of Dox, and are normalized to the results
obtained with wt HCT116 cells. Normalization was performed to compensate for unspecific inhibitory effects of prolonged Dox treatment. Data are representative of
three independent experiments performed in triplicate.
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need to further assess Src function(s) in experimental models
relevant to those human cancers in which Src is over-
expressed. We developed a single-step inducible gene ex-
pression approach (SMV system) and applied it to investigate
the consequences of increasing c-Src levels and activity on
the growth of human colorectal cancer cells.
Our results clearly demonstrate that elevations in c-Src
levels and activity do not promote the proliferation of HCT116
and SW480 cells. In fact, we have shown that a constitutively
active mutant of c-Src (c-SrcY527F) might have growth-
inhibitory consequences if expressed at very high levels.
These data contrast with proliferation-promoting effects of
the overexpression of v-Src and c-SrcY527F in fibroblasts
and further substantiate the need formore detailed studies on
the role of c-Src in cell cycle progression in defined human
epithelial cell contexts. Although we cannot exclude that
inducing Src might trigger proliferative response in some
other colorectal cancer cell types, based on the results
presented, it seems reasonable to speculate that there might
be no simple correlation between c-Src level/activity and the
growth rate of tumor cells in the late stages of colorectal
carcinogenesis. Consequently, in advanced colorectal carci-
nomas, c-Src inhibitors might be more effective than tumor
growth in suppressing other processes (e.g., invasion and
metastasis). Indeed, there is emerging evidence in support of
such scenario [16]. It is still possible, however, that c-Src
promotes cell proliferation at earlier phases of colorectal
carcinogenesis (e.g., at dysplastic epithelium stage) and that
a certain level of endogenous c-Src activity is required for the
continued growth of colorectal carcinoma cells. In this re-
spect, there are reports that c-Src might be involved in tumor
angiogenesis and that inhibiting c-Src activity can suppress
cancer cell growth [34–36].Without doubt, further studies are
required to fully characterize the role of c-Src at diverse
stages of colorectal carcinogenesis. Such studies might
provide invaluable insights into c-Src function and help to
optimize the use of Src inhibitors in colorectal cancer therapy.
Figure 6. Consequences of low-level and high-level induction of c-SrcY527F
in SW480 colorectal cancer cells. Histogram shows cell numbers in induced
and uninduced SW480 Luc-Src527F Low, SW480 Luc-Src527F High, and
parental SW480 cells 24 hours after Dox treatment. Data are based on three
independent experiments performed in triplicate. SW480 Luc-SrcY527F High
cells displayed a significantly decreased total cell number following induction
with Dox compared to noninduced cells (two-sided t-test, P < .05). No
statistically significant differences were found between the numbers of wt
SW480 and SW480 Luc-Src527F Low cells in the presence and in the
absence of Dox (P > .05). Western blot analysis illustrates increases in the
amount of Src following Dox induction.
Figure 7. Consequences of the induction of wt c-Src (A) and c-SrcY527F (B) on the growth of HCT116 cells in a xenograft model. There were at least five animals
in each control group and Dox-treated group. Successful gene induction in Dox-treated animals was confirmed using luciferase reporter assay (histogram insert).
The use of a Dox-containing diet did not affect animal body weight during the experiment (line-plot insert).
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Supplementary Information for Materials and Methods
Electron Microscopy Studies
Trypsinized adherent cells and detached cells obtained
48 hours after Dox treatment were spun gently (for 3 minutes
at 800 rpm in a standard bench-top centrifuge) and washed
twice or thrice with freshly prepared Soerensen’s buffer.
[This is obtained by adding 95 ml of KH2PO4 solution
(2.04 g/100 ml) to 405 ml of Na2HPO4 (2H2O) solution
(13.34 g/500 ml), which results in a 0.15-M buffer at pH 7.4.]
The cells were fixed with 2.5% glutaraldehyde and 1% OsO4
(each fixative was prepared in Soerensen’s buffer). Each
fixation step took 1 hour and was followed by three washes
with Soerensen’s buffer. The samples were subsequently
dehydrated by incubation (5 minutes each) in increasing
concentrations of ethanol (30%, 50%, 70%, 95%, and
100%; 3). This was followed by embedding in Spurr’s resin
[1]. Infiltration steps were performed as follows: 1:3 resin/
acetone for 1 hour; 1:1 resin/acetone for 1 hour; 3:1 resin/
acetone for 1 hour; 100% resin for 1 hour; 100% resin over-
night. Samples were subsequently embedded in fresh resin
in Beem capsules 00 (Agar Scientific Ltd., Stansed, UK) for
48 hours at 70jC. Sections were cut at a thickness of 60 nm
using an Ultratrim 45 diamond knife (Diatome, Biel, Switzer-
land)mounted on a LeicaUltracut S (LeicaMicrosystemsAG,
Wetzlar, Austria) and collected on 200-mesh 3.05-mmcopper
grids (Agar Scientific Ltd.). Sections were poststained, 5 min-
utes in each, with 2% uranyl acetate in 70% ethanol followed
byReynolds lead citrate [2]. Sectionswere imaged on a JEOL
1220 TEM (JEOL UK Ltd., Welwyn Garden City, UK) at an
accelerating voltage of 80 kV, and images were collected
using a SiS Megaview II CCD camera (Soft Imaging Systems
Gmbh, Munster, Germany).
Cell Cycle Analysis
For cell cycle analysis, 7.89  105 cells were seeded into
duplicate T75 tissue culture flasks. Three days later, when
cells were in the logarithmic phase of growth as determined
by growth curves (Figure W4), Dox was added to one of the
flasks, and both were harvested 24 hours later. They were
then trypsinized, counted, and adjusted to a density of 2 
106 cells/ml (final volume). Cells were spun at 350g for
4 minutes, the medium was aspirated, and 1.3 ml of ice-cold
PBS was added while vortexing. Three milliliters of absolute
ethanol (at 20jC) was added while vortexing (i.e., final
mixture, 70% ethanol). Cells were left for fixing overnight at
4jC. Cells were resuspended in 1 ml of PBS containing
20 mg/ml propidium iodide (cat. no. P4864; Sigma) and
1 mg/ml RNAse A (cat. no. R4875; Sigma), and incubated at
37jC for 30 minutes. Flow cytometry was performed on a
Becton Dickinson FACSCalibur machine (Becton Dickinson,
San Jose, CA) set at 4250-mV excitation using a 488-nm
laser line. Forward scatter and orthogonal light scatter were
collected together with red fluorescence (DNA-bound pro-
pidium iodide; 585 ± 21 nm, linear scale). Cell clumps were
excluded by fluorescence pulse processing. Cell cycle anal-
ysis of collected data was performed using ModFitLT Ver-
sion 2.0 software (Verity Software House, Topsham, ME).
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Figure W1.Western blot analyses illustrating the phosphorylation of selected downstream effectors of c-Src in indicated HCT116 clones grown for 24 hours in the
presence or in the absence of induction. Results are representative of at least two independent cell preparations.
Figure W2. Cell cycle profiles of parental HCT116 cells, HCT116 LucwtSrc
cells (clone wt23), and HCT116 Luc-Src527F Low cells (clone LowY12)
obtained after 24 hours of growth in the presence or in the absence of Dox.
Data are representative of three independent experiments.
Figure W3. Representative pictures showing lack of apoptotic nuclei among
HCT116 Luc-Src527F cells (clone High Y50) and HCT116 Luc-only control
cells (clone Luc C6) irrespective of Dox induction. Similar results have been
obtained with other clones tested.
Figure W4. Growth curves from Figure 1D presented individually for each clone.
